ArticleBMC ophthalmology2025
Safety and efficacy of limited laser therapy for type I mid-zone II retinopathy of prematurity.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaser photocoagulation of the entire avascular retina is a conventional therapy for the proliferative stage of retinopathy of prematurity (ROP). Limited lasers in number, localized at the avascular area posterior to the ridge might similarly regress aberrant retinal neovascularization. The study aims to evaluate the safety and efficacy of an innovative modified posterior half avascular area laser therapy for type I mid-zone II ROP.
methodsIn a prospective comparative study, 48 eyes of 24 premature infants with bilateral symmetric type 1 zone II ROP were included for laser photocoagulation. The first eye received standard panavascular photocoagulation. In the second eye, laser photocoagulation was applied to the posterior half of the retinal avascular area, sparing the anterior half retinal avascular area. The retreatment rate was determined as a main outcome measure through weekly funduscopic examination. Fundus photography and refractive measurement were obtained at the last follow-up.
resultsThe mean birth weight of the infants was 1341.04 ± 353.55 g. The infants’ mean postmenstrual age (PMA) at the time of intervention was 38.25 ± 2.95 weeks. In 2 (8.33%) infants, both eyes were retreated with complete regression without further recurrence. No adverse events were observed during mean PMA follow-up of 54.47 ± 4.09 weeks. The mean spherical equivalent was comparable between the two groups at the last follow-up (P = 0.794).
conclusionLimited laser photocoagulation demonstrated a safety and efficacy profile similar to that of standard therapy in type I ROP in the mid-zone II. A randomized clinical trial is mandatory to validate the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.